Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy

Journal of Substance Abuse Treatment

Volumn 26, Issue 2, 2004, Pages 67-78

  Avants, S Kelly ^a   Margolin, Arthur ^a   Usubiaga, Mary Helen ^a   Doebrick, Cheryl ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; HIV; Methadone; Opiates; Psychotherapy

Indexed keywords

METHADONE;

ABSTINENCE; ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SAFE SEX; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ADULT; ANALGESICS, OPIOID; BEHAVIOR THERAPY; COCAINE-RELATED DISORDERS; CONDOMS; COSTS AND COST ANALYSIS; FEMALE; HARM REDUCTION; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MOTIVATION; NEEDLE SHARING; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 1642422254     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(03)00159-4     Document Type: Article

References (69)

1. Addis M. Evaluating the treatment manual as a means of disseminating empirically validated psychotherapies. Clinical Psychology. 4:1997;1-11.
2. Avants, S. K. (1998). HIV Risk reducation and coping skills training group for cocaine and opioid dependent patients. Unpublished assessment and treatment manual. Available: www.3-S.us.
3. Avants S.K. Comprehensive methadone maintenance treatment: What is the optimal level of ancillary psychosocial services? Medicine & Behavior. 2(2):1999;40.
4. Avants, S. K. (2001). The Holistic Harm Reduction Program for HIV-positive injection drug users (HHRP+). Yale University School of Medicine, Substance Abuse Center, 34 Park Street, New Haven, CT 06519. Available: www.3-S.us.
5. Avants S.K., Margolin A., Kosten T.R., Rounsaville B.J., Schottenfeld R.S. When is less treatment better? Role of social anxiety on matching methadone patients to psychosocial treatments. Journal of Consulting and Clinical Psychology. 66(6):1998;924-931.
6. Avants S.K., Margolin A., Kosten T.R., Sindelar J.L., Rounsaville B.J., Schottenfeld R., Stine S., Cooney N.L., Li S.H., Rosenheck R. Day treatment vs enhanced standard methadone services for opioid-dependent patients: A comparison of clinical efficacy and cost. American Journal of Psychiatry. 156(1):1999;27-33.
7. Avants S.K., Margolin A., McMahon T.J., Kosten T.R. Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. Addictive Behaviors. 22(5):1997;599-611.
8. Avants S.K., Warburton L.A., Hawkins K.A., Margolin A. Continuation of high risk behaviors by HIV-positive drug users: Treatment implications. Journal of Substance Abuse Treatment. 19(1):2000;15-22.
9. Baker A., Heather N., Wodak A., Dixon J., Holt P. Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. AIDS. 7(2):1993;247-256.
10. Ball J.C., Ross A. The effectiveness of methadone maintenance treatment. 1991;Springer-Verlag, New York.
11. Bedimo A.L., Pinkerton S.D., Cohen D.A., Gray B., Farley T.A. Condom distribution: a cost-utility analysis. International Journal of STD & AIDS. 13:2002;384-392.
12. Bryan A.D., Fisher J.D., Fisher W.A., Murray D.M. Understanding condom use among heroin addicts in methadone maintenance using the information- motivation-behavioral skills model. Substance Use & Misuse. 35(4):2000;451-471.
13. Bux D.A., Lamb R.J., Iguchi M.Y. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug and Alcohol Dependence. 37:1995;29-35.
14. Calsyn D.A., Saxon A.J., Freeman G., Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. American Journal of Public Health. 82:1992;573-575.
15. Caplehorn J.R.M., Ross M.W. Methadone maintenance and the likelihood of risky needle-sharing. The International Journal of the Addictions. 30(6):1995;685-698.
16. Carey M.P., Braaten L.S., Maisto S.A., Gleason J.R., Forsyth A.D., Durant L.E., Jaworski B.C. Using information, motivational enhancement, and skills training to reduce the risk of HIV infection for low-income urban women: A second randomized clinical trial. Health Psychology. 19(1):2000;3-11.
17. Carroll K.M. Manual-guided psychosocial treatment: A new virtual requirement for pharmacotherapy trials. Archives of General Psychiatry. 54:1997;923-928.
18. Carroll K.M., Nich C., Sifry R.L., Nuro K.F., Frankforter T.L., Ball S.A., Fenton L., Rounsaville B.J. A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions. Drug & Alcohol Dependence. 57(3):2000;225-238.
19. Centers for Disease Control and Prevention. (2000). HIV/AIDS Surveillance Report (Vol. 12(2)). Washington, DC: Centers for Disease Control and Prevention.
20. Centers for Disease Control and Prevention. (1999, November, revised). Compendium of HIV prevention interventions with evidence of effectiveness. Atlanta, GA: Author.
21. Childress A.R., McLellan A.T., Woody G.E., O'Brien C.P. Are there minimum conditions necessary for methadone maintenance to reduce intravenous drug use and AIDS risk behaviors? NIDA Research Monographs. 106:1991;167-177.
22. Copenhaver M., Avants S.K., Margolin A., Warburton L.A. Intervening effectively with drug abusers infected with HIV: Taking into account the potential for cognitive impairment. Journal of Psychoactive Drugs. 35(2):2003;209-218.
23. Fisher J.D., Fisher W.A. Theoretical approaches to individual-level change in HIV risk behavior. Peterson J.L., DiClemente R.J. Handbook of HIV Prevention. 2000;3-56 Kluwer Academic/Plenum Publishers, New York.
24. Fisher J.D., Misovich S.J., Kimble D., Weinstein E. Dynamics of HIV risk behavior in HIV-infected injecting drug users. AIDS and Behavior. 3(1):1999;41-57.
25. French M.T., McGeary K.A., Chitwood D.D., McCoy C.B. Chronic illicit drug use, health services utilization and the cost of medical care. Social Science & Medicine. 50(12):2000;1703-1713.
26. Gibson D.R., Flynn N.M., McCarthy J.J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 13(14):1999;1807-1818.
27. Gossop M., Marsden J., Stewart D., Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: Results from the National Treatment Outcome Research Study. AIDS Care. 14(1):2002;77-93.
28. Grella C., Anglin M.D. Implementing an enhanced methadone maintenance program for HIV risk reduction in Los Angeles. Fletcher B.W., Inciardia J.A., Horton A.M. Drug abuse treatment: The implementation of innovative approaches. 1994;3-18 Greenwood Press, Westport, CT.
29. Grella C.E., Anglin M.D., Wugalter S.E. Cocaine and crack use and HIV risk behavior among high-risk methadone maintenance clients. Drug and Alcohol Dependence. 37:1995;15-21.
30. Grella C.E., Anglin M.D., Wugalter S.E. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. American Journal of Drug and Alcohol Abuse. 23(1):1997;15-42.
31. Grella C.E., Etheridge R.M., Joshi V., Anglin M.D. Delivery of HIV risk-reduction services in drug treatment programs. Journal of Substance Abuse Treatment. 19(3):1999;229-237.
32. Hartel D.M., Schoenbaum E.E. Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Public Health. 113(Suppl 1):1999;107-115.
33. Helweg-Larson M., Collins B.E. The UCLA Multidimensional Condom Attitude Scale: Documenting the complex determinants of condom use in college students. Health Psychology. 13:1994;224-237.
34. Hoffmann J. HIV and drug abuse: brothers and sisters (video). Silver Spring, MD: Danya International, Inc.
35. Holtgrave D.R., Pinkerton S.D. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. Journal of Acquired Immune Deficiency Syndrome. 16:1997;54-62.
36. Holtgrave D.R., Pinkerton S.D., Merson M. Estimating the cost of unmet HIV-prevention needs in the United States. American Journal of Preventive Medicine. 23(1):2002;7-12.
37. Joe G.W., Simpson D.D. HIV risks, gender, and cocaine use among opiate users. Drug & Alcohol Dependence. 37(1):1995;23-28.
38. Kahn J.G., Washington A.E., Showstack J.A., Berlin M., Phillips K. Updated estimates of the impact and cost of HIV prevention in injection drug users. Report prepared for the (US) Centers for Disease Control. 1992;Institute for Health Policy Studies, San Francisco.
39. Kalichman S.C., DiFonzo K., Kyomugrsha F., Simpson D., Presser K., Bjordstrom B. When briefer can be better: Single session approaches to HIV risk reduction interventions. InterAmerican Journal of Psychology. 35:2001;41-58.
40. Kamb M.L., Fishbein M., Douglas J.M. Efficacy of risk-reduction counseling to prevent human immunodeficienty virus and sexually transmitted diseases: A randomized controlled trial. JAMA. 280:1998;1161-1167.
41. Kolar A.F., Brown B.S., Weddington W.W., Ball J.C. A treatment crisis: Cocaine use by clients in methadone-maintenance programs. Journal of Substance Abuse Treatment. 7:1990;101-107.
42. Kraft M.K., Rothbard A.B., Hadley T.R., McLellan A.T., Asch D.A. Are supplementary services provided during methadone maintenance really cost-effective? American Journal of Psychiatry. 154(9):1997;1214-1219.
43. Kwiatkowski C.F., Booth R.E. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. Journal of Acquired Immune Deficiency Syndrome. 26(5):2001;483-489.
44. Margolin A., Avants S.K., Warburton L.A., Hawkins K.A., Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychology. 22(2):2003;223-228.
45. McLellan A.T., Alterman A.I., Cacciol J., Metzger D., O'Brien C.P. A new measure of substance abuse treatment: Initial studies of the Treatment Service Review. Journal of Nervous and Mental Disease. 180:1992;101-110.
46. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association. 269(15):1993;1953-1959.
47. Miller W.R., Rollnick S. Motivational Interviewing. Preparing people to change addictive behavior. 1991;Guilford Press, New York.
48. Murphy D.A., Stein J.A., Schlenger W., Maibach E. Conceptualizing the multidimensional nature of self-efficacy: Assessment of situational context and level of behavioral challenge to maintain safer sex. Health Psychology. 20(4):2001;281-290.
49. National Institute on Drug Abuse Outreach/risk reduction strategies for changing HIV-related risk behaviors among injection drug users. The National AIDS Demonstration Research (NADR) Project (NIH Publication No. 94-3726). 1994;National Institutes of Health, Washington, DC.
50. O'Leary A. Multisite NIMH HIV Prevention Trial Group Social-cognitive theory mediators of behavior change in the National Institute of Mental Health Multisite HIV Prevention Trial. Health Psychology. 20(5):2001;369-376.
51. O'Neill K., Baker A., Cooke M., Collins E., Heather N., Wodak A. Evaluation of a cognitive-behavioural intervention for pregnant injecting drug users at risk of HIV infection. Addiction. 91(8):1996;1115-1125.
52. Peipman, F. E. W., Dévieux, J. G., Malow, R. M., Lucenko, B. A., Feaster, D. J., & Kalichman, S. C. (2001). An evaluation of the Information, Motivation, and Behavior (IMB) Model among severely mentally ill substance abusers. Paper presented at the National HIV Prevention Conference (August 12-15, 2001), Atlanta, GA.
53. Pinkerton S.D., Holtgrave D.R., DiFranceisco W.J., Stevenson L.Y., Kelly J.A. Cost-effectiveness of a community-level HIV risk reduction intervention. American Journal of Public Health. 88(8):1998;1239-1242.
54. Rawson R.A., Huber A., McCann M., Shoptaw S., Farabee D., Reiber C., Ling W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry. 59:2002;817-824.
55. Rawson R.A., McCann M.J., Hasson A.J., Ling W. Cocaine abuse among methadone patients: Are there effective treatment strategies. Journal of Psychoactive Drugs. 26:1994;129-136.
56. Rhoades H.M., Creson D., Elk R., Schmitz J., Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health. 88(1):1998;34-39.
57. Rosenheck R., Neale M., Frisman L. Issues in estimating the cost of innovative mental health programs. Psychiatric Quarterly. 66(1):1995;9-31.
58. Schilling R.F., el-Bassel N., Hadden B., Gilbert L. Skills-training groups to reduce HIV transmission and drug use among methadone patients. Social Work. 40(1):1995;91-101.
59. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs methadone maintenance treatment for concurrent opioid-dependence and cocaine abuse. Archives of General Psychiatry. 54:1997;713-720.
60. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., Banys P., Hall S.M. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 283(10):2000;1303-1310.
61. Semaan S., Des Jarlais D.C., Sogolow E., Johnson W.D., Hedges L.V., Ramirez G., Flores S.A., Norman L., Sweat M.D., Needle R.H. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. Journal of Acquired Immune Deficiency Syndrome. 30:2002;S73-S93.
62. Semaan S., Kay L., Strouse D., Sogolow E., Mullen P.D., Neumann M.S., Flores S.A., Peersman G., Johnson W.D., Lipman P.D., Eke A., Des Jarlais D.C. A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction. Journal of Acquired Immune Deficiency Syndrome. 30:2002;S30-S50.
63. Simpson D.D., Joe G.W., Dansereau D.F., Chatham L.R. Strategies for improving methadone treatment process and outcomes. Journal of Drug Issues. 27(2):1997;239-260.
64. Sorensen J.L., Copeland A.L. Drug abuse treatment as an HIV prevention strategy: A review. Drug & Alcohol Dependence. 59(1):2000;17-31.
65. Sorensen J.L., London J., Heitzmann C., Gibson D.R., Morales E.S., Dumontet R., Acree M. Psychoeducational group approach: HIV risk reduction in drug users. AIDS Education and Prevention. 6(2):1994;95-112.
66. Strathdee S.A., Galai N., Safaiean M., Celentano D.D., Vlahov D., Johnson L., Nelson K.E. Sex differences in risk factors for HIV seroconversion among injection drug users. Archives of Internal Medicine. 161:2001;1281-1288.
67. Teichner G., Horner M.D., Harvey R.T. Neuropsychological predictors of the attainment of treatment objectives in substance abuse patients. International Journal of Neuroscience. 106(3-4):2001;253-263.
68. Zaric G.S., Brandeau M.L., Barnett P.G. Methadone maintenance and HIV prevention: A cost-effectiveness analysis. Management Science. 46(8):2000;1013-1031.
69. Zarkin G.A., Lindrooth R.C., Demiralp B., Wechsberg W. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV. Health Services Research. 36(2):2001;335-355.